Fulcrum Therapeutics
FULC
66 hedge funds and large institutions have $256M invested in Fulcrum Therapeutics in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
57% more capital invested
Capital invested by funds: $163M → $256M (+$92.8M)
20% more funds holding
Funds holding: 55 → 66 (+11)
5.72% more ownership
Funds ownership: 75.02% → 80.74% (+5.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$10.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.95M |
| 3 |
BlackRock
New York
|
+$4.34M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$5.6M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.11M |
| 3 |
CC
Casdin Capital
New York
|
-$2.26M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.94M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$978K |
FULC Hedge Fund Activity: Q4 2020 in Review
66 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2020, worth a combined $256M — up 57% from $163M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new FULC positions and 3 closed out — a net gain of 11 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was RTW Investments, adding an estimated $10.4M. The largest seller was Boxer Capital, exiting entirely with an estimated $5.6M sold.
- 66 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2020, up from 55 in Q3 2020.
- Funds reported $256M of Fulcrum Therapeutics stock for Q4 2020, up 57% quarter-over-quarter.
- 14 funds opened new Fulcrum Therapeutics positions in Q4 2020 and 3 closed out, a net change of +11 holders.
- The largest Fulcrum Therapeutics buyer in Q4 2020 was RTW Investments, an estimated $10.4M added.
- The largest Fulcrum Therapeutics seller in Q4 2020 was Boxer Capital, an estimated $5.6M sold.
Based on aggregated 13F filings for Q4 2020.